Dana Investment Advisors, Inc. Altimmune, Inc. Transaction History

Dana Investment Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$3.45 - $5.97 $3,753 - $6,495	1,088 Added 1.89%	58,740 $207,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $241,561 - $970,283	57,652 New	57,652 $243,000
Q4 2021 Feb 09, 2022	SELL	$8.69 - $12.48 $179,318 - $257,524	-20,635 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$8.43 - $16.81 $43,667 - $87,075	5,180 Added 33.52%	20,635 $233,000
Q2 2021 Aug 10, 2021	BUY	$9.85 - $16.46 $152,231 - $254,389	15,455 New	15,455 $152,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Dana Investment Advisors, Inc. with notifications on news.